第三产程:预防不良母婴结局的循证实践
本文综述第三产程生理及预防产后出血的干预措施,指出当前证据支持使用有效药物预防产后出血、延迟结扎脐带、早期皮肤接触及在可行时采用控制性牵拉脐带。作者建议不再使用「第三产程主动管理」这一组合干预术语,改用「第三产程照护」。
要点
- 阴道分娩后预防产后出血最有效的宫缩剂方案包括缩宫素联合麦角新碱、缩宫素联合米索前列醇或卡贝缩宫素。
- 剖宫产分娩后,卡贝缩宫素或缩宫素单次推注是最有效的方案。
- 作者建议不再使用「第三产程主动管理」作为组合干预术语,改用「第三产程照护」。
核心结论
- 当前证据支持使用有效药物预防产后出血、延迟结扎脐带、早期皮肤接触及在可行时采用控制性牵拉脐带。
- 作者建议不再使用「第三产程主动管理」作为组合干预术语,改用「第三产程照护」。
研究设计与样本
- 本文为综述,检索并汇总预防产后出血及促进母婴健康的干预措施证据,并回顾当前全球指南与推荐。
主要发现
- 阴道分娩后预防产后出血最有效的宫缩剂方案包括缩宫素联合麦角新碱、缩宫素联合米索前列醇或卡贝缩宫素。
- 剖宫产分娩后,卡贝缩宫素或缩宫素单次推注是最有效的方案。
- 在所有分娩后预防产后出血时,与单用宫缩剂相比,宫缩剂联合氨甲环酸的证据不一致。
关键数值与推荐
- 回顾选定国际指南发现,「第三产程主动管理」一词仍在使用,但针对各单项干预的推荐不一,且不一定有当前证据支持。
临床怎么用
- 作者建议不再使用「第三产程主动管理」作为组合干预术语,改用「第三产程照护」,以促进实施对妇女和新生儿均安全有益的循证干预。
- 使用特定预防策略的决定取决于患者和系统层面因素,包括患者合并症、费用及资源和人员可及性差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The third stage of labor is defined as the time period between delivery of the fetus through delivery of the placenta. During a normal third stage, uterine contractions lead to separation and expulsion of the placenta from the uterus. Postpartum hemorrhage is a relatively common complication of the third stage of labor. Strategies have been studied to mitigate the risk of postpartum hemorrhage, leading to the widespread implementation of active management of the third stage of labor. Initially, active management of the third stage of labor consisted of a bundle of interventions including administration of a uterotonic agent, early cord clamping, controlled cord traction, and external uterine massage. However, the effectiveness of these interventions as a bundle has been questioned, leading to abandonment of some components in recent years. Despite this, upon review of selected international guidelines, we found that the term "active management of the third stage of labor" was still used, but recommendations for and against individual interventions were variable and not necessarily supported by current evidence. In this review, we: (1) examine the physiology of the third stage of labor, (2) present evidence related to interventions that prevent postpartum hemorrhage and promote maternal and neonatal health, (3) review current global guidelines and recommendations for practice, and (4) propose future areas of investigation. The interventions in this review include pharmacologic agents to prevent postpartum hemorrhage, cord clamping, cord milking, cord traction, cord drainage, early skin-to-skin contact, and nipple stimulation. Treatment of complications of the third stage of labor is outside of the scope of this review. We conclude that current evidence supports the use of effective pharmacologic postpartum hemorrhage prophylaxis, delayed cord clamping, early skin-to-skin contact, and controlled cord traction at delivery when feasible. The most effective uterotonic regimens for preventing postpartum hemorrhage after vaginal delivery include oxytocin plus ergometrine; oxytocin plus misoprostol; or carbetocin. After cesarean delivery, carbetocin or oxytocin as a bolus are the most effective regimens. There is inconsistent evidence regarding the use of tranexamic acid in addition to a uterotonic compared with a uterotonic alone for postpartum hemorrhage prevention after all deliveries. Because of differences in patient comorbidities, costs, and availability of resources and staff, decisions to use specific prevention strategies are dependent on patient- and system-level factors. We recommend that the term "active management of the third stage of labor" as a combined intervention no longer be used. Instead, we recommend that "third stage care" be adopted, which promotes the implementation of evidence-based interventions that incorporate practices that are safe and beneficial for both the woman and neonate.
引用
- Hersh AR, Carroli G, Hofmeyr GJ, et al. Third stage of labor: evidence-based practice for prevention of adverse maternal and neonatal outcomes. Am J Obstet Gynecol. 2023. PMID: 38462248. doi:10.1016/j.ajog.2022.11.1298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。